RNAi - technologies, markets and companies

The markets for RNAi are difficult to define as no RNAi-based product is in clinical development yet. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. It is estimated to be $400 million currently in 2005,$850 million by the year 2010 and $1.2 billion by the year 2015. The value of the drug discovery market based on RNAi can be assessed at $650 million in the year 2005, increasing to $1 billion in the year 2010 and $1.5 billion in 2015. Even if a few products get into the market by the year 2010, this market will expand to $3.5 billion based on revenues from sales of RNAi- based drugs and increase further to $5.9 billion in 2015. Markets are also analyzed according to breakdown of technologies and use of siRNAs, miRNAs, etc.

Profiles of 119 companies involved in developing RNAi technologies are presented along with 84 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Approximately 15 of these are developing RNAi-based therapeutics. The bibliography contains selected 250 publications that are cited in the report. The text is supplemented with 24 tables and 7 figures.

Published: May 2005 Pages: 282
Table of Contents

Price
Single User Print Version $2,000.00
Electronic Site License (pdf + one print copy) $1,800.00